Dogwood Therapeutics (DWTX) News Today $5.24 -0.06 (-1.13%) Closing price 05/23/2025 04:00 PM EasternExtended Trading$5.20 -0.04 (-0.76%) As of 05/23/2025 07:44 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Headlines Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesOwnershipSEC FilingsTrendsBuy This Stock DWTX Latest News All Sources Trusted Sources MarketBeat Benzinga Bloomberg GlobeNewswire GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha TalkMarkets The Street TipRanks The Wall Street Journal Wall Street Zen Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent May 2025 April 2025 March 2025 February 2025 January 2025 December 2024 November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 September 2022 August 2022 July 2022 June 2022 Time Period Zacks Small Cap Has Bearish Forecast for DWTX Q2 EarningsMay 17, 2025 | americanbankingnews.comDWTX: Phase 2b Trial in Chemotherapy Induced Neuropathic Pain Underway…May 14, 2025 | finance.yahoo.comDogwood Therapeutics Stock Short Interest Report | NASDAQ:DWTX | BenzingaMay 9, 2025 | benzinga.comDogwood Therapeutics Announces First Quarter 2025 Financial ResultsMay 8, 2025 | finance.yahoo.comDogwood Therapeutics Announces First Quarter 2025 Financial ResultsMay 8, 2025 | globenewswire.comHC Wainwright & Co. Upgrades Dogwood Therapeutics (DWTX)April 24, 2025 | msn.comDogwood receives Nasdaq confirmation of complianceApril 11, 2025 | markets.businessinsider.comDogwood Therapeutics, Inc. Receives Nasdaq Confirmation of ComplianceApril 11, 2025 | financialpost.comDogwood Therapeutics, Inc. Receives Nasdaq Confirmation of ComplianceApril 11, 2025 | globenewswire.comDogwood management to meet with MaximApril 9, 2025 | markets.businessinsider.comDWTX: Interim Data for Phase 2b Trial in 4Q25…April 5, 2025 | msn.comDogwood regains Nasdaq complianceApril 4, 2025 | markets.businessinsider.comDogwood Therapeutics, Inc. Regains Nasdaq ComplianceApril 3, 2025 | globenewswire.comDogwood Therapeutics Announces Fourth Quarter and Full Year 2024 Financial ResultsMarch 31, 2025 | globenewswire.comDogwood doses first patient in Phase 2b trial of HalneuronMarch 18, 2025 | markets.businessinsider.comDWTX: First Patient Dosed in Phase 2b Trial of Halneuron in CINP; Debt Conversion Strengthens Balance Sheet…March 18, 2025 | msn.comDogwood Therapeutics Announces Dosing of First Patient in Phase 2b Trial Evaluating Halneuron® in Patients with Chemotherapy-Induced Neuropathic PainMarch 18, 2025 | globenewswire.comMaxim Group Remains a Buy on Dogwood Therapeutics (DWTX)March 13, 2025 | markets.businessinsider.comDogwood Therapeutics, Inc. Announces Pricing of $4.8 Million Registered Direct Offering of Common Stock Priced At-The-Market Under Nasdaq RulesMarch 13, 2025 | financialpost.comDogwood Therapeutics, Inc. Announces Conversion of Existing $19.5M in Debt to Equity, Strengthening Balance Sheet Moving ForwardMarch 12, 2025 | financialpost.comDogwood Therapeutics IncMarch 10, 2025 | cnn.comDogwood Therapeutics Becomes Most Actively Discussed Biotech Stock Among Retail Traders After Stunning 370% SurgeJanuary 25, 2025 | msn.comDogwood Therapeutics Announces Patient Dosing in Phase 2b Trial Evaluating Halneuron® in Patients with Chemotherapy Induced Neuropathy (CINP) to Commence First Quarter of 2025January 21, 2025 | globenewswire.com Get Dogwood Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for DWTX and its competitors with MarketBeat's FREE daily newsletter. Email Address DWTX Media Mentions By Week DWTX Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. DWTX News Sentiment▼-1.000.77▲Average Medical News Sentiment DWTX News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. DWTX Articles This Week▼01▲DWTX Articles Average Week Get Dogwood Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for DWTX and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies RVPH News CELU News ITRM News TNYA News NRXP News ELYM News RANI News ALGS News SPRO News LVTX News Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:DWTX) was last updated on 5/25/2025 by MarketBeat.com Staff From Our PartnersWhite House to reset Social Security?Elon Musk's parting DOGE gift looks set to shock America... A single announcement by July 22nd could soon b...Altimetry | SponsoredA grave, grave error.I thought what happened 25 years ago was a once- in-a-lifetime event… but how wrong I was. Because here we...Porter & Company | SponsoredCollect $7k per month from Tesla’s SECRET dividendTesla doesn't pay a traditional dividend.... But I just discovered a secret backdoor to collect a secret 69...Investors Alley | SponsoredWhy Elon put $51 million into thisWhy Elon Musk Just Invested $51 Million Into Brand New “Miracle Metal” Developed by MIT ScientistsTrue Market Insiders | SponsoredElon’s NEXT Big IPO?Cancel your internet TODAY!? Take your latest internet bill and light it on fire… then count the seconds it...Banyan Hill Publishing | SponsoredThe one deadline Elon can't afford to miss...For years, Elon Musk made headlines for blowing past deadlines — so often that investors coined a nickname for...Brownstone Research | Sponsored3..2..1.. AI 2.0 ignition (don’t sleep on this)I just put together an urgent new presentation that you need to see right away. In short: I believe we are...Timothy Sykes | SponsoredPrepare now for May 31 eventPrepare now for May 31 event Circle May 31 on your calendar This man grew up in a trailer in New Mexico. To...Stansberry Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Dogwood Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Dogwood Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.